{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:23:40Z","timestamp":1788485020303,"version":"build-2803163510"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Characteristics of peritoneal membrane is unique and individually different in peritoneal dialysis patients. Relationship between specific nature of peritoneal transport, anemia and inflammation has not yet been extensively studied. We attempted to outline the complex interplay of several biomarkers of iron status and their association with peritoneal transport, degree of inflammation and residual renal function.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 58 patients treated with peritoneal dialysis either CAPD or APD for at least 3 months were enrolled in this study. Full blood count, traditional markers of iron status (transferrin saturation-TSAT and ferritin), serum erythroferrone-ERFE, soluble transferrin receptor (sTfR), hepcidin, zonulin, growth differentiation factor\u2009\u221215 (GDF15), IL-16, hsCRP and hypoxia-inducible factor\u2014\u03b1 (HIF-1-\u03b1; in serum and dialysate) were measured using commercially available tests. We also performed Peritoneal Equilibrium Test and assessed GFR level.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Hb levels above 10\u2009g\/dL was found in 74% of patients. Hb levels positively correlated with residual renal function and nutritional status. Adequate iron status was diagnosed in 69% of subjects, only in 9% of patients, criteria for absolute iron deficiency were met. Serum ERFE correlated inversely with hepcidin levels but was not associated with erythropoietin stimulating agent dose. Peritoneal transport had strong correlation with dialysate sTfR (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.05), dialysate hepcidin (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.05), dialysate GDF15 (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.01) and dialysate zonulin (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001) levels, as well as serum IL6 (<jats:italic>p<\/jats:italic>\u2009=\u20090.03), serum hs-CRP (<jats:italic>p<\/jats:italic>\u2009=\u20090.04) and dialysate hs-CRP (<jats:italic>p<\/jats:italic>\u2009=\u20090.04).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Residual kidney function contributes considerably to better control of anemia. Various degree of inflammation is inherent to PD patients. Additionally, fast-average peritoneal transport is associated with greater degree of inflammation and higher concentration of markers of iron status, GDF15 and zonulin in dialysate. This finding may indicate more effective clearance of higher-range middle molecules in fast-average transporters. The role of ERFE as a marker of erythropoiesis in PD patients requires further investigation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1148094","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T19:22:37Z","timestamp":1688671357000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Iron status and anemia control are related to peritoneal membrane properties in peritoneally dialyzed patients"],"prefix":"10.3389","volume":"10","author":[{"given":"Tomasz","family":"G\u0142ogowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Wojtaszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Malyszko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1053\/j.ajkd.2017.09.026","article-title":"Update on anemia in ESRD and earlier stages of CKD: core curriculum 2018","volume":"71","author":"Fishbane","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanism of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3747\/pdi.2018.00249","article-title":"International anemia prevalence and management in peritoneal dialysis patients","volume":"39","author":"Perlman","year":"2019","journal-title":"Perit Dial Int"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.25796\/bdd.v2i4.23613","article-title":"Hepatic iron load differs strikingly between peritoneal dialysis and hemodialysis patients","volume":"2","author":"Rostoker","year":"2019","journal-title":"Bull Dial Domic"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e0143430","DOI":"10.1371\/journal.pone.0143430","article-title":"The different association between serum ferritin and mortality in hemodialysis and peritoneal dialysis patients using Japanese nationwide dialysis registry","volume":"10","author":"Maruyama","year":"2015","journal-title":"PLoS One"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.numecd.2020.12.018","article-title":"Abnormal iron status is associated with increased risk of mortality in patients on peritoneal dialysis","volume":"31","author":"Luo","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3747\/pdi.2018.00052","article-title":"The iron biology status of peritoneal dialysis patients may be a risk factor for development of infectious peritonitis","volume":"39","author":"Aldriwesh","year":"2019","journal-title":"Perit Dial Int"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.3390\/nu14081613","article-title":"Association of abnormal iron status with the occurrence and prognosis of peritoneal dialysis\u2014related peritonitis: a longitudinal data-based 10-year retrospective study","volume":"14","author":"Diao","year":"2022","journal-title":"Nutrients"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"909373","DOI":"10.1155\/2014\/909373","article-title":"Clinical causes of inflammation in peritoneal dialysis patients","volume":"2014","author":"Cho","year":"2014","journal-title":"Int J Nephrol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1681\/ASN.2013030314","article-title":"Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival","volume":"24","author":"Lambie","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/aor.14001","article-title":"Oxidative stress, inflammation, and peritoneal dialysis: a molecular biology approach","volume":"45","author":"Innico","year":"2021","journal-title":"Artif Organs"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1159\/000210038","article-title":"Intravenous iron sucrose changes the intraperitoneal homeostasis","volume":"28","author":"Breborowicz","year":"2009","journal-title":"Blood Purif"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.26402\/jpp.2020.3.07","article-title":"N-acetylcysteine modulates effect of the iron isomaltoside on peritoneal mesothelial cells","volume":"71","author":"Misian","year":"2020","journal-title":"J Physiol Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"876","DOI":"10.3109\/08860220903216071","article-title":"Type of renal replacement therapy and residual renal function may affect prohepcididn and hepcidin","volume":"31","author":"Malyszko","year":"2009","journal-title":"Ren Fail"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3390\/ph12030123","article-title":"Unraveling hepcidin plasma protein binding: evidence from peritoneal equilibration testing","volume":"12","author":"Diepeveen","year":"2019","journal-title":"Pharmaceutic"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s11255-019-02362-4","article-title":"Efficacy and safety of a low monthly dose of intravenous iron sucrose in peritoneal dialysis patients","volume":"52","author":"Mitsopoulos","year":"2020","journal-title":"Int Urol Nephrol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1038\/sj.ki.5002600","article-title":"Benefits of preserving residual renal function in peritoneal dialysis","volume":"73","author":"Marron","year":"2008","journal-title":"Idney Int Suppl"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1007\/s40620-022-01388-9","article-title":"On the importance of the interplay of residual renal function with clinical outcomes in end-stage kidney disease","volume":"35","author":"Tanriover","year":"2022","journal-title":"J Nephrol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.2215\/CJN.01430121","article-title":"Association of Plasma Uremic Solute Levels with residual kidney function in children on peritoneal Dialysis","volume":"16","author":"Ganesan","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e0151601","DOI":"10.1371\/journal.pone.0151601","article-title":"Association among erythroferrone and biomarkers of erythropoiesis and iron metabolism, and treatment with long-term erythropoiesis stimulating agents in patients on hemodialysis","volume":"11","author":"Honda","year":"2016","journal-title":"PLoS One"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.3324\/haematol.2017.181743","article-title":"Levels of the erythropoietin -responsive hormone erythroferrone in mice and humans with chronic kidney disease","volume":"103","author":"Hanudel","year":"2018","journal-title":"Hematologica"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3390\/jcm8040523","article-title":"Serum erythroferrone levels associate with mortality and cardiovascular events in hemodialysis and CKD patients: a two cohort study","volume":"8","author":"Spoto","year":"2019","journal-title":"J Clin Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1053\/j.ajkd.2014.06.030","article-title":"Peritoneal solute transport and inflammation","volume":"64","author":"Davies","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1093\/ndt\/gfp767","article-title":"Impact of systemic and local peritoneal inflammation on peritoneal solute transport rate in new peritoneal dialysis patients: a 1-year prospective study","volume":"25","author":"Cho","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fmed.2019.00210","article-title":"The behavior of the type of peritoneal transport in the inflammatory and oxidative status in adults under peritoneal Dialysis","volume":"6","author":"Gutierrez-Prieto","year":"2019","journal-title":"Front Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"239476","DOI":"10.1155\/2012\/239476","article-title":"Serum hepcidin levels and reticulocyte hemoglobin concentrations as indicators of the iron status of peritoneal dialysis patients. Int","volume":"2012","author":"Eguchi","year":"2012","journal-title":"J Nephrol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1177\/089686080802800420","article-title":"Hepcidin is linked to anemia and inflammation in peritoneal dialysis patients","volume":"28","author":"Malyszko","year":"2008","journal-title":"Perit Dial Int"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1038\/s41598-017-04664-y","article-title":"Serum hepcidin may be a novel uremic toxin, which might be related to erythropoietin resistance","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"685448","DOI":"10.3389\/fmed.2021.684548","article-title":"Serum Hepcidin-25 and risk of mortality in patients on peritoneal dialysis","volume":"8","author":"Zhong","year":"2021","journal-title":"Front Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s11255-020-02663","article-title":"Biomarkers of iron metabolism in chronic kidney disease","volume":"53","author":"Tomasz","year":"2021","journal-title":"Int Urol Nephrol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1080\/0886022X.2019.1635893","article-title":"Hepcidin and diabetes are independently related with soluble transferrin receptor levels in chronic dialysis patients","volume":"41","author":"Belo","year":"2019","journal-title":"Ren Fail"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e1251384","DOI":"10.1080\/21688370.2016.1251384","article-title":"Zonulin, a regulator of epithelial and endothelial barrier functions, and itsinvolvement in chronic inflammatory diseases","volume":"4","author":"Strugeona","year":"2016","journal-title":"Tiss Barriers"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1007\/s11255-020-02756-9","article-title":"Advances in the role and mechanism of zonulin pathway in kidney diseases","volume":"53","author":"Yu","year":"2021","journal-title":"Int Urol Nephrol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s11255-016-1495-5","article-title":"Relationship between plasma levels of zonulin, bacterial lipopolysaccharides, d -lactate and markers of inflammation in haemodialysis patients","volume":"49","author":"Ficek","year":"2017","journal-title":"Int Urol Nephrol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1159\/000368512","article-title":"Iron status and inflammation in early stages of chronic kidney disease","volume":"40","author":"Lukaszyk","year":"2015","journal-title":"Kidney Blood Press Res"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11255-017-1741-5","article-title":"Zonulin, inflammation and iron status in patients with early stages of chronic kidney disease","volume":"50","author":"Lukaszyk","year":"2018","journal-title":"Int Urol Nephrol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1016\/j.transproceed.2014.09.018","article-title":"Zonulin, iron status, and anemia in kidney transplant recipients: are they related?","volume":"46","author":"Malyszko","year":"2014","journal-title":"Transplant Proc"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3389\/fimmu.2020.00951","article-title":"Growth\/differentiation Factor-15 (GDF-15): from biomarker to novel targetable immune checkpoint","volume":"11","author":"Wischhusen","year":"2020","journal-title":"Front Immunol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s11255-016-1278-z","article-title":"GDF-15, iron, and inflammation in early chronic kidney disease among elderly patients","volume":"48","author":"Lukaszyk","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1159\/000351810430","article-title":"GDF15 is related to Anemia and Hepcidin in kidney allograft recipients","volume":"123","author":"Malyszko","year":"2013","journal-title":"Nephron Clin Pract"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1186\/s12882-020-02046-7","article-title":"Hepcidin and GDF-15 are potential biomarkers of iron deficiency anaemia in chronic kidney disease patients in South Africa","volume":"21","author":"Nalado","year":"2020","journal-title":"BMC Nephrol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1080\/1354750X.2016.1201534","article-title":"Epidermal growth factor, growth differentiation factor-15, and survivin as novel biocompatibility markers in children on chronic dialysis","volume":"21","author":"Bargenda","year":"2016","journal-title":"Biomarkers"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1148094\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T19:22:42Z","timestamp":1688671362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1148094\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":42,"alternative-id":["10.3389\/fmed.2023.1148094"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1148094","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,6]]},"article-number":"1148094"}}